key: cord-0961322-gx4jbeo7
authors: Spaccarotella, Carmen; Sorrentino, Sabato; Indolfi, Ciro
title: Reduction of hospitalisations and increased mortality for acute coronary syndromes during covid-19 era: Not all countries are equal
date: 2021-07-06
journal: Lancet Reg Health West Pac
DOI: 10.1016/j.lanwpc.2021.100155
sha: 4a61d8a5ec34e6465b549119cd1c9d04c4db3cd0
doc_id: 961322
cord_uid: gx4jbeo7

nan

Data by Daniel Chan and colleagues [1] from "All New Zealand Acute Coronary Syndrome Quality Improvement Registry", a nationwide web-based electronic database, recently published in The Lancet Regional Health -Western Pacific , examined all patients admitted to an New Zealand Hospital with Acute Coronary Syndromes (ACS) who underwent coronary angiography during the lockdown (23 March -26 April 2020) respect with equivalent weeks in 2015-2019. Ambulance attendances and regional community troponin-I testing were also compared for lockdown and nonlockdown (1 July 2019 to 16 February 2020) periods.

In the study by Daniel Chan and colleagues [1] , hospitalisations for ACS for 5 weeks during the lockdown were analysed; the results documented a clear reduction in hospitalisations (105 vs. 146 per-week, rate ratio 0 · 72 [95% CI 0 · 61-0 · 83], p = 0.003). In particular, the major component of this reduction involved myocardial infarctions without ST-segment elevation (NSTE-ACS; p = 0 · 002), while there were no significant differences in ST-segment elevation heart attacks (STEMI; p = 0 · 31) and door to balloon time (70 vs. 72 min, p = 0 · 52). In addition, the authors reported an increase in percutaneous revascularisation (59% vs. 49%, p < 0 · 001) compared to surgical revascularisation (9% vs. 15%, p = 0 · 005) in the context of NSTE ACS. Also, fewer ambulance attendances for cardiac arrest (98 vs. 110 per-week, p = 0 · 04) but no difference for suspected ACS (408 vs. 420 per-week, p = 0 ·.44) and, above all, a marked reduction in community troponin testing were reported throughout the lockdown (182 vs. 394 per-week, p < 0 · 001). The main finding of the study was that, despite the low incidence of COVID-19 during the period of this survey in New Zealand, there was a nationwide decrease in ACS hospitalisations during the lockdown.

The issue of the number of hospitalisations for ACS during the pandemic has been addressed in many studies (see Table 1 ) [1] [2] [3] [4] [5] .

The first study that described a reduction in the hospitalisation of patients with ACS during the pandemic was performed in Italy [2] in consecutive patients admitted in the cardiac care units (CCU) during the week of 12-19 March 2020, compared with the same period in 2019 [ 3 , 4 ] . A total of 319 AMIs were recorded during the 1 week in 2020, compared with 618 in the previous year, corresponding to a 48.4% reduction [2] . There was a 26.5% reduction in STEMI admissions and a 65.4% reduction in NSTEMI admissions [2] .

Therefore, unlike Chan's study [1] , the Italian data [2] had shown, in the first European nation hit by the pandemic and with a high incidence of COVID-19, that the reduction in hospitalisations affected patients with NSTEMI ad well as with STEMI. The reduction in hospitalisations for STEMI, as it was easy to predict, was associated with an increase in the mortality rate (13.7% in 2020 versus 4.1% in 2019) [2] . The delay in hospitalisation (due both to patients' fear of going to the emergency room and the healthcare system clogged by COVID-19) has led to an increase in the rate of major complications (cardiogenic shock, life-threatening arrhythmias, heart rupture, post-infarct interventricular septal defect, and severe post-ischemic mitral regurgitation). These complications increased significantly in 2020 (from 18.8% compared to 10.4% in the previous year) [2] . The COVID-19 pandemic also caused significant disruption of the urgency pathways in myocardial infarction, with a 39.2% increase in the time from symptom onset to coronary angiography and a 31.5% increase of the time from first medical contact to coronary revascularisation [2] . By carrying out a more detailed analysis, in the context of STEMI, the reduction in hospitalisations was more frequent in women than in men (41.2% versus 17.8%). Other cardiac diseases, in addition to ACS, showed a decrease in hospitalisations: a net reduction in ICU admissions was recorded during the week of March 2020 compared to the equivalent week in 2019 for heart failure (-46.8 %) and atrial fibrillation (-53.4%) [2] .

The reduction in the hospitalisations for ACS has been reported in many other studies. An estimated 38% reduction in STEMI activations was showed by US cardiac catheterisation laboratories [ 5 , 6 ] while a 40% reduction was reported in Spain [7] .

The reasons for the reduced hospitalisations of ACS during the pandemic are still poorly understood and many hypotheses could explain this phenomenon. Various reasons discouraged patients to be admitted to the hospital: the lockdown, the fear of contracting the virus in the hospital setting, social isolation, and the difficulty, at least in the initial phase and the lack of separated "clean" paths. In phase I of the pandemic the clean pathways for ACS patients were not been established discouraging patients (and physicians) to require hospitalisation. The new fast-track ruling out COVID-19 protocol now allows access to the Cath lab without infection risk and should widely be applied [8] . On the other hand, it cannot be completely excluded that a potentially real reduction in acute cardiovascular events is due to low physical stress and greater rest at home during quarantine. However, this hypothesis does not explain the delay observed between symptom onset and hospital admissions for STEMI [9] , as well as the increased hospital mortality and complication rates [2] .

In conclusion, regulatory agencies should take into account that, even in the COVID-19 era, primary PCI is the standard of care for all STEMI patients and PCI is also the preferred strategy of therapy in all high-risk NSTEMI patients. Protected regional transports, fasttrack ruling out COVID-19, safe treatment for ACS patients, and inhospital protection all health care personnel should be organised.

These recommendations will need to be adapted to each regional system's PCI Center and EMS system to avoid an unnecessary reduction in hospitalisations of ACS patients during the pandemic [10] .

All Authors have no conflicts of interest to disclose

The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

The outbreak of COVID-19 in Italy: fighting the pandemic

The effects of COVID-19 on general cardiology in Italy

Reduction in STsegment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España

Fast-track ruling in/out SARS-CoV-2 infection with rapid 0/1.5 h molecular test in patients with acute coronary syndromes

Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong

Management of acute myocardial infarction during the COVID-19 pandemic